UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000055014 |
|---|---|
| Receipt number | R000062852 |
| Scientific Title | Study on effect of the intestinal barrier function by ingesting lactic acid bacteria |
| Date of disclosure of the study information | 2025/06/30 |
| Last modified on | 2024/07/18 19:25:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study on effect of the intestinal barrier function by ingesting lactic acid bacteria
Acronym
Study on effect of the intestinal barrier function by ingesting lactic acid bacteria
Scientific Title
Study on effect of the intestinal barrier function by ingesting lactic acid bacteria
Scientific Title:Acronym
Study on effect of the intestinal barrier function by ingesting lactic acid bacteria
Region
| Japan |
Condition
Condition
Not applicable
Classification by specialty
| Not applicable |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine the effect of the lactic acid bacteria consumed for 12 weeks on intestinal barrier index.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Assessment
Primary outcomes
Intestinal barrier indexes of urine, blood, and feces
Key secondary outcomes
Defecation status, Inflammation markers, Clinical laboratory values, Fecal examination, Izumo scale, POMS2 short version, SF-36v2 acute version, OSA-MA
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Daily intake one packet (1g) of test food for 12 weeks
Interventions/Control_2
Daily intake one packet (1g) of placebo (control food) for 12 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1. Males and females aged more than or equal to 18, and less than 65 when obtaining the consent
2. Subjects whose BMI is 25 or more in the screening
3. Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the present study and being able to sign a written informed consent
Key exclusion criteria
1. Subjects who have been reported to have galactosemia
2. Subjects who have history of gastrointestinal surgical procedures or who have undergone endoscopic removal of polyps within one year prior to obtaining the informed consent
3. Subjects who take food or supplement which have the possibility to affect the results of the present study more than 4 days a week before 1 months of informed consent
4. Subjects who can't restrict food or supplement which have the possibility to affect the results of the present study from the observation period to the present study period
5. Subjects who take medications that may affect bowel symptoms or non-steroidal anti-inflammatory drugs such as aspirin more than 3 days a week before 1 months of informed consent
6. Subjects who have taken antibiotics before 2 months of informed consent
7. Subjects who can't restrict taking OTC drugs, quasi-drugs, supplements, or health foods from the day before the examination until the completion of the examination
8. Subjects who are expected to undergo a major change in their home, work, or other living environment during the research period and who have difficulty participating in or continuing research
9. Subjects who are smokers
10. Subjects who have abdominal symptoms by ingesting dairy products
11. Subjects with food allergies
12. Subjects who are pregnant or lactating, or intending to become pregnant during the study
13. Subjects who had participated in other clinical trials within the past month
14. Subjects suffering from or undergoing treatment for diabetes, digestive diseases, heart disease, thyroid disease, adrenal disease, and other metabolic diseases
15. Subjects who tested positive for hepatitis B virus or hepatitis C virus in the screening
16. Subjects deemed unsuitable for the present study by the investigator
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Toshihiro |
| Middle name | |
| Last name | Sashihara |
Organization
Meiji Holdings Co., Ltd.
Division name
Wellness Science Labs
Zip code
192-0919
Address
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
TEL
042-632-5842
toshihiro.sashihara@meiji.com
Public contact
Name of contact person
| 1st name | Toshihiro |
| Middle name | |
| Last name | Sashihara |
Organization
Meiji Holdings Co., Ltd.
Division name
Wellness Science Labs
Zip code
192-0919
Address
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
TEL
042-632-5842
Homepage URL
toshihiro.sashihara@meiji.com
Sponsor or person
Institute
Meiji Holdings Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Meiji Holdings Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
Address
Daiwa Building 2F, 3-3-10, Nihombashihongoku, Chuo, Tokyo, Japan
Tel
03-6225-9005
IRB@cpcc.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 06 | Month | 30 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2024 | Year | 06 | Month | 17 | Day |
Date of IRB
| 2024 | Year | 06 | Month | 14 | Day |
Anticipated trial start date
| 2024 | Year | 08 | Month | 19 | Day |
Last follow-up date
| 2024 | Year | 11 | Month | 26 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2024 | Year | 07 | Month | 18 | Day |
Last modified on
| 2024 | Year | 07 | Month | 18 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062852
